(Circulation. 2000;101:1358.)
© 2000 American Heart Association, Inc.
Brief Rapid Communications |
L-NMMA (a Nitric Oxide Synthase Inhibitor) is Effective in the Treatment of Cardiogenic Shock
From the Cardiology Institute (G.C., E.K., A.B., O.M., A.S., D.A., Z.V.), Clinical Pharmacology Research Unit (G.C., E.K., A.B., O.M., Y.Moshkovitz, R.Z., A.S., D.A., Y.Mihovitz, M.M., Z.V.), and Department of Medicine "A" (A.G.), Assaf-Harofeh Medical Center, Zerifin, Israel.
Correspondence to Gad Cotter, MD, The Cardiology Institute, Assaf-Harofeh Medical Center, 70300, Zerifin, Israel.
Background—The objective was to assess the safety and efficacy of L-NMMA in the treatment of cardiogenic shock.
Methods—We enrolled 11 consecutive patients with cardiogenic shock that persisted after >24 hours from admission, despite coronary catheterization and primary percutaneous transluminal coronary revascularization, when feasible, and treatment with mechanical ventilation, intraaortic balloon pump (IABP), and high doses of catecholamines. L-NMMA was administered as an IV bolus of 1 mg/kg and continuous drip of 1 mg · kg-1 · h-1 for 5 hours. Treatment with catecholamines, mechanical ventilation, and IABP was kept constant throughout the study.
Results—Within 10 minutes of L-NMMA administration, mean arterial blood pressure (MAP) increased from 76±9 to 109±22 mm Hg (+43%). Urine output increased within 5 hours from 63±25 to 156±63 cc/h (+148%). Cardiac index decreased during the steep increase in MAP from 2.0±0.5 to 1.7±0.4 L/(min · m2) (-15%); however, it gradually increased to 1.85±0.4 L/(min · m2) after 5 hours. The heart rate and the wedge pressure remained stable. Twenty-four hours after L-NMMA discontinuation, MAP (+36%) and urine output (+189%) remained increased; however, cardiac index returned to pretreatment level. No adverse events were detected. Ten out of eleven patients could be weaned off mechanical ventilation and IABP. Eight patients were discharged from the coronary intensive care unit, and seven (64%) were alive at 1-month follow-up.
Conclusions—L-NMMA administration in patients with cardiogenic shock is safe and has favorable clinical and hemodynamic effects.
Key Words: cardiogenic shock • hypotension • L-NMMA
This article has been cited by other articles:
 |
|
 |
|
  F. R. Heinzel, P. Gres, K. Boengler, A. Duschin, I. Konietzka, T. Rassaf, J. Snedovskaya, S. Meyer, A. Skyschally, M. Kelm, et al. Inducible Nitric Oxide Synthase Expression and Cardiomyocyte Dysfunction During Sustained Moderate Ischemia in Pigs Circ. Res., November 7, 2008; 103(10): 1120 - 1127. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Nicholls, Z. Wang, R. Koeth, B. Levison, B. DelFraino, V. Dzavik, O. W. Griffith, D. Hathaway, J. A. Panza, S. E. Nissen, et al. Metabolic Profiling of Arginine and Nitric Oxide Pathways Predicts Hemodynamic Abnormalities and Mortality in Patients With Cardiogenic Shock After Acute Myocardial Infarction Circulation, November 13, 2007; 116(20): 2315 - 2324. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. A. Harrington, J. H. Alexander, J. S. Hochman, H. R. Reynolds, V. Dzavik, and F. J. Van de Werf Tilarginine in Patients With Acute Myocardial Infarction and Cardiogenic Shock Reply JAMA, September 5, 2007; 298(9): 972 - 973. [Full Text] [PDF]
|
|
|
|
 |
|
 V. Dzavik, G. Cotter, H. R. Reynolds, J. H. Alexander, K. Ramanathan, A. L. Stebbins, D. Hathaway, M. E. Farkouh, E. M. Ohman, D. A. Baran, et al. Effect of nitric oxide synthase inhibition on haemodynamics and outcome of patients with persistent cardiogenic shock complicating acute myocardial infarction: a phase II dose-ranging study Eur. Heart J., May 1, 2007; 28(9): 1109 - 1116. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Ndrepepa, A. Schomig, and A. Kastrati Lack of Benefit From Nitric Oxide Synthase Inhibition in Patients With Cardiogenic Shock: Looking for the Reasons JAMA, April 18, 2007; 297(15): 1711 - 1713. [Full Text] [PDF]
|
|
|
|
|
|
The TRIUMPH Investigators Effect of Tilarginine Acetate in Patients With Acute Myocardial Infarction and Cardiogenic Shock: The TRIUMPH Randomized Controlled Trial JAMA, April 18, 2007; 297(15): 1657 - 1666. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Franco-Cereceda, P. Holm, F. Bredin, and C. Adding Attenuation of postoperative noradrenaline need by nitric oxide inhibition using L-NMMA Eur J Heart Fail, December 1, 2005; 7(7): 1180 - 1182. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kohsaka, V. Menon, A. M. Lowe, M. Lange, V. Dzavik, L. A. Sleeper, J. S. Hochman, and for the SHOCK Investigators Systemic Inflammatory Response Syndrome After Acute Myocardial Infarction Complicated by Cardiogenic Shock Arch Intern Med, July 25, 2005; 165(14): 1643 - 1650. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. S. Duvernoy and E. R. Bates Management of Cardiogenic Shock Attributable to Acute Myocardial Infarction in the Reperfusion Era J Intensive Care Med, July 1, 2005; 20(4): 188 - 198. [Abstract] [PDF]
|
|
|
|
|
|
P. Libby and P. Theroux Pathophysiology of Coronary Artery Disease Circulation, June 28, 2005; 111(25): 3481 - 3488. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A G C Sutton, P Finn, J A Hall, A A Harcombe, R A Wright, and M A de Belder Predictors of outcome after percutaneous treatment for cardiogenic shock Heart, March 1, 2005; 91(3): 339 - 344. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Nordhaug, T. Steensrud, E. Aghajani, C. Korvald, and T. Myrmel Nitric oxide synthase inhibition impairs myocardial efficiency and ventriculo-arterial matching in acute ischemic heart failure Eur J Heart Fail, October 1, 2004; 6(6): 705 - 713. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. E. Bretscher, H. Li, T. L. Poulos, and O. W. Griffith Structural Characterization and Kinetics of Nitric-oxide Synthase Inhibition by Novel N5-(Iminoalkyl)- and N5-(Iminoalkenyl)-ornithines J. Biol. Chem., November 21, 2003; 278(47): 46789 - 46797. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Lim, M.-J. Dubois, D. De Backer, and J.-L. Vincent Do All Nonsurvivors of Cardiogenic Shock Die With a Low Cardiac Index? Chest, November 1, 2003; 124(5): 1885 - 1891. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. A. Sanborn, L. A. Sleeper, J. G. Webb, J. K. French, G. Bergman, M. Parikh, S. C. Wong, J. Boland, M. Pfisterer, J. N. Slater, et al. Correlates of one-year survival inpatients with cardiogenic shock complicating acute myocardial infarction: Angiographic findings from the SHOCK trial J. Am. Coll. Cardiol., October 15, 2003; 42(8): 1373 - 1379. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. G. Webb, A. M. Lowe, T. A. Sanborn, H. D. White, L. A. Sleeper, R. G. Carere, C. E. Buller, S. C. Wong, J. Boland, V. Dzavik, et al. Percutaneous coronary intervention for cardiogenic shock in the SHOCK trial J. Am. Coll. Cardiol., October 15, 2003; 42(8): 1380 - 1386. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. B. Granger, K. W. Mahaffey, W. D. Weaver, P. Theroux, J. S. Hochman, T. G. Filloon, S. Rollins, T. G. Todaro, J. C. Nicolau, W. Ruzyllo, et al. Pexelizumab, an Anti-C5 Complement Antibody, as Adjunctive Therapy to Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction: The COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) Trial Circulation, September 9, 2003; 108(10): 1184 - 1190. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Cotter, Y. Moshkovitz, E. Kaluski, O. Milo, Y. Nobikov, A. Schneeweiss, R. Krakover, and Z. Vered The role of cardiac power and systemic vascular resistance in the pathophysiology and diagnosis of patients with acute congestive heart failure Eur J Heart Fail, August 1, 2003; 5(4): 443 - 451. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Menon Cardiogenic shock: have we really found the magic potion? Eur. Heart J., July 2, 2003; 24(14): 1279 - 1281. [Full Text] [PDF]
|
|
|
|
|
|
G. Cotter, E. Kaluski, O. Milo, A. Blatt, A. Salah, A. Hendler, R. Krakover, A. Golick, and Z. Vered LINCS: L-NAME (a NO synthase inhibitor) In the treatment of refractory Cardiogenic Shock: A prospective randomized study Eur. Heart J., July 2, 2003; 24(14): 1287 - 1295. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Hochman Cardiogenic Shock Complicating Acute Myocardial Infarction: Expanding the Paradigm Circulation, June 24, 2003; 107(24): 2998 - 3002. [Full Text] [PDF]
|
|
|
|
|
|
V. Menon and J. S Hochman MANAGEMENT OF CARDIOGENIC SHOCK COMPLICATING ACUTE MYOCARDIAL INFARCTION Heart, December 1, 2002; 88(5): 531 - 537. [Full Text] [PDF]
|
|
|
|
 |
|
 K. O. Kisich, M. Higgins, G. Diamond, and L. Heifets Tumor Necrosis Factor Alpha Stimulates Killing of Mycobacterium tuberculosis by Human Neutrophils Infect. Immun., August 1, 2002; 70(8): 4591 - 4599. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Cotter, Y. Moshkovitz, O. Milovanov, A. Salah, A. Blatt, R. Krakover, Z. Vered, and E. Kaluski Acute heart failure: a novel approach to its pathogenesis and treatment Eur J Heart Fail, June 1, 2002; 4(3): 227 - 234. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Wagner, K. Hu, J. Bauersachs, J. Karcher, M. Wiesler, S. K. Goparaju, G. Kunos, and G. Ertl Endogenous cannabinoids mediate hypotension after experimental myocardial infarction J. Am. Coll. Cardiol., December 1, 2001; 38(7): 2048 - 2054. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Scherrer-Crosbie, R. Ullrich, K. D. Bloch, H. Nakajima, B. Nasseri, H. T. Aretz, M. L. Lindsey, A.-C. Vancon, P. L. Huang, R. T. Lee, et al. Endothelial Nitric Oxide Synthase Limits Left Ventricular Remodeling After Myocardial Infarction in Mice Circulation, September 11, 2001; 104(11): 1286 - 1291. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A New Therapy for Cardiogenic Shock Journal Watch (General), March 31, 2000; 2000(331): 8 - 8. [Full Text]
|
|